English
Français
Deutsch
Italiano
Русский
Español
हिन्दी
简体中文
한국어
日本語
Company Participants
Chad Fugure – Vice President of Investor Relations
Jan Mikkelsen – President, CEO, Member of Executive Board & Executive Director
Scott Smith – CFO, Executive VP & Member of Executive Board
Jay Wu – Executive VP & President of Ascendis US
Aimee Shu – Executive VP & Chief Medical Officer
Conference Call Participants
Jessica Fye – JPMorgan Chase & Co, Research Division
Tazeen Ahmad – BofA Securities, Research Division
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Research Division
Yaron Werber – TD Cowen, Research Division
Heidi Jacobson – Leerink Partners LLC, Research Division
Derek Archila – Wells Fargo Securities, LLC, Research Division
Daniel Bronder – Cantor Fitzgerald & Co., Research Division
Eliana Merle – Barclays Bank PLC, Research Division
Leland Gershell – Oppenheimer & Co. Inc., Research Division
Kyuwon Choi – Goldman Sachs Group, Inc., Research Division
Yun Zhong – Wedbush Securities Inc., Research Division
Luca Issi – RBC Capital Markets, Research Division
Maxwell Skor – Morgan Stanley, Research Division
Alexander Thompson – Stifel, Nicolaus & Company, Incorporated, Research Division
Kalpit Patel – Wolfe Research, LLC
Faisal Ali Khurshid
Presentation
Operator
Thank you for standing by, and welcome to the Ascendis Pharma Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, today’s program is being recorded.
And now I’d like to introduce your host for today’s program, Chad Fugure, Vice President, Investor Relations. Please go ahead, sir.
Chad Fugure
Vice President of Investor Relations
Thank you, operator, and thank you, everyone, for joining our full year 2025 financial results conference call. I’m Chad Fugure, Vice President, Investor Relations at Ascendis Pharma. Joining me on the call today are Jan Mikkelsen, President and Chief Executive Officer; Scott Smith, Chief Financial Officer; Sherrie Glass, Chief Business Officer; Jay Wu, Executive Vice President and President, Ascendis U.S.; and Aimee Shu, Chief Medical Officer.
Read the full article here
